Tentt

Life Biosciences Closes $80M Series D Financing

Closed
HealthcareOther

Deal Overview

Life Biosciences, a clinical-stage biotechnology company focused on cellular rejuvenation therapies, has closed a fully-subscribed $80 million Series D financing. The company will use proceeds to support operations into the second half of 2027.

Funding will include completion of its recently initiated Phase 1 clinical trial of ER-100 in optic neuropathies and continued advancement of its Partial Epigenetic Reprogramming (PER) platform across multiple therapeutic indications. ER-100’s Phase 1 trial is designed to assess safety and tolerability in patients with open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION).

Key Details

Target
Life Biosciences
Deal Size
$50M – $100M
Reported Value
$80 million

Filed under

Source

Read full article on globenewswire.com

via GlobeNewswire — Financing · April 8, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call

Related Deals

See all Healthcare deals →